Meeting Banner
Abstract #3832

Evaluation of the novel SPIO GEH121333 for monitoring changes in tumor vascularity and vascular permeability after anti-angiogenic treatment using susceptibility contrast and T1-mapping

Else Marie Huuse 1,2 , Jana Cebulla 2 , Dan E Meyer 3 , Karina Langseth 4 , Siver Andre Moestue 2 , and Tone Frost Bathen 2

1 Department of medical Imaging, St. Olavs University Hospital, Trondheim, Norway, 2 MI lab and Department of Circulation and Medical Imaging, Norwegian University of Science and Technology, Trondheim, Norway, 3 Biomedical Imaging & Physiology Laboratory, GE Global Research Center, Niskayuna, NY, United States, 4 GE Healthcare AS, Oslo, Norway

Preclinical-phase iron oxide particles (GEH121333), with a relatively large diameter and a high r1/r2 rate was used for monitoring vascular response to bevacizumab treatment in ovarian xenografts. Changes in T2 and T2* relaxation rate was used for calculation marker for the blood vessel density Q= Capital Greek Delta R2/( Capital Greek Delta R2* 2/3 ) and post contrast tissue T1 after clearance of iron particles from the blood pool was used as a measure for changed tumor vessel permeability. The results suggest that the novel GEH121333 particles can be used to detect vascular changes after anti-angiogenic therapy and that their magnetic properties allow evaluation of changes both in T1 and susceptibility imaging, attributable to underlying changes in permeability and blood vessel density, respectively.

This abstract and the presentation materials are available to members only; a login is required.

Join Here